Adeno-Associated Viral Vectors Market Growth Outlook Through 2024-2033

Overview and Scope
Adeno-associated viral vectors (AAV) are small, non-pathogenic viruses commonly used in gene therapy. They are engineered to deliver therapeutic genes into target cells, offering potential treatments for genetic disorders, cancers, and other diseases. AAV’s safety profile and ability to efficiently infect both dividing and non-dividing cells make them valuable tools in biomedical research and clinical applications.

Sizing and Forecast
The adeno-associated viral vectors market size has grown rapidly in recent years. It will grow from $2.29 billion in 2023 to $2.69 billion in 2024 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to vaccine development, increased funding and investment, academic and industrial collaborations, expansion of clinical trials, and public awareness and advocacy.

The adeno-associated viral vectors market size is expected to see rapid growth in the next few years. It will grow to $5.17 billion in 2028 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to expanding therapeutic applications, increasing the prevalence of genetic disorders, and neurological disorders, regulatory approvals and support, and cost reductions in production. Major trends in the forecast period include gene therapy advancements, technological innovations, scalable manufacturing processes, collaborations and investments, and technological advancements.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Segmentation & Regional Insights
The adeno-associated viral vectors market covered in this report is segmented –

1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies
2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas
4) By Scale Of Operation: Preclinical, Clinical, Commercial
5) By Application Area: Gene Therapy, Cell Therapy, Vaccines

North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of genetic disorders is expected to propel the growth of the adeno-associated viral vectors market going forward. Genetic disorders are conditions caused by abnormalities in an individual’s DNA, leading to physical or developmental abnormalities. The improved diagnostic techniques, greater awareness, and higher reproductive age, along with environmental factors and genetic drift are leading to the rise in the prevalence of genetic disorders. Adeno-associated viral vectors are utilized in gene therapy for genetic disorders, delivering corrective genes into target cells to potentially treat conditions like muscular dystrophy or cystic fibrosis. For instance, in February 2023, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, congenital diseases caused an estimated 240,000 baby deaths globally within 28 days of birth each year. An additional 170,000 children between the ages of 1 month and 5 years die as a result of congenital diseases. Therefore, the increasing prevalence of genetic disorders is driving the adeno-associated viral vectors market.

Key Industry Players
Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

The adeno-associated viral vectors market report table of contents includes:

 

1. Executive Summary
2. Adeno-Associated Viral Vectors Market Characteristics
3. Adeno-Associated Viral Vectors Market Trends And Strategies
4. Adeno-Associated Viral Vectors Market – Macro Economic Scenario
5. Global Adeno-Associated Viral Vectors Market Size and Growth
.
.
.
32. Global Adeno-Associated Viral Vectors Market Competitive Benchmarking
33. Global Adeno-Associated Viral Vectors Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Adeno-Associated Viral Vectors Market
35. Adeno-Associated Viral Vectors Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On: 
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model